FDA’s Benefit/Risk Framework Will Focus On Communication, Not Quantification
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Director Woodcock tells BIO’s International Conference that the agency’s effort to formalize its approach to risk/benefit assessments will produce better sharing of approval conundrums, but not necessarily a mathematical solution to those problems.
You may also be interested in...
Benefit-Risk Assessment Framework Moves Toward Global Harmonization
PhRMA shifts further development of its structured benefit-risk assessment framework to the European organization CIRS, which has relationships with regulators in Europe, the U.S. and elsewhere that can drive the framework’s adoption for the drug approval process.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.